Your browser is no longer supported. Please, upgrade your browser.
Settings
AZN [NASD]
AstraZeneca PLC
Index- P/E44.08 EPS (ttm)1.22 Insider Own0.50% Shs Outstand2.62B Perf Week3.01%
Market Cap136.78B Forward P/E16.58 EPS next Y3.23 Insider Trans0.00% Shs Float2.60B Perf Month9.00%
Income3.20B PEG2.31 EPS next Q0.52 Inst Own15.90% Short Float4.13% Perf Quarter7.30%
Sales26.62B P/S5.14 EPS this Y137.20% Inst Trans0.88% Short Ratio10.26 Perf Half Y5.99%
Book/sh5.95 P/B9.02 EPS next Y53.46% ROA5.20% Target Price63.60 Perf Year0.34%
Cash/sh3.13 P/C17.11 EPS next 5Y19.10% ROE25.10% 52W Range46.48 - 64.94 Perf YTD7.32%
Dividend1.40 P/FCF514.22 EPS past 5Y1.70% ROI12.20% 52W High-17.39% Beta0.56
Dividend %2.61% Quick Ratio0.80 Sales past 5Y1.50% Gross Margin80.00% 52W Low15.43% ATR0.94
Employees76100 Current Ratio1.00 Sales Q/Q11.20% Oper. Margin19.40% RSI (14)62.89 Volatility1.97% 1.31%
OptionableYes Debt/Eq1.30 EPS Q/Q223.30% Profit Margin12.00% Rel Volume0.70 Prev Close52.93
ShortableYes LT Debt/Eq1.15 EarningsApr 30 BMO Payout112.50% Avg Volume10.46M Price53.65
Recom1.50 SMA204.40% SMA507.17% SMA2001.90% Volume7,359,156 Change1.36%
Apr-12-21Downgrade Argus Buy → Hold
Mar-16-21Upgrade Jefferies Hold → Buy
Feb-25-21Upgrade UBS Neutral → Buy
Jan-15-21Initiated Deutsche Bank Buy
Dec-07-20Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20Upgrade UBS Sell → Neutral
Nov-11-20Upgrade HSBC Securities Reduce → Hold
Sep-29-20Initiated Berenberg Buy
Nov-22-19Initiated SVB Leerink Outperform
Oct-25-19Upgrade Liberum Hold → Buy
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
May-06-21 03:13AM  
May-05-21 07:09PM  
07:00PM  
06:37PM  
06:03PM  
03:49PM  
03:41PM  
02:06PM  
11:08AM  
08:58AM  
07:51AM  
07:08AM  
05:58AM  
01:52AM  
01:15AM  
May-04-21 03:35PM  
03:18PM  
02:54PM  
02:44PM  
02:02PM  
08:14AM  
06:07AM  
05:00AM  
03:59AM  
02:14AM  
May-03-21 02:32PM  
11:39AM  
10:53AM  
09:00AM  
08:50AM  
07:41AM  
06:14AM  
04:09AM  
May-02-21 09:31PM  
08:00PM  
Apr-30-21 08:00PM  
06:20PM  
05:10PM  
04:27PM  
03:31PM  
02:44PM  
02:35PM  
01:37PM  
12:20PM  
12:01PM  
11:24AM  
11:14AM  
11:04AM  
10:59AM  
10:55AM  
10:28AM  
10:19AM  
08:18AM  
08:11AM  
07:34AM  
07:29AM  
07:04AM  
06:30AM  
05:42AM  
05:05AM  
04:38AM  
04:12AM  
02:36AM  
02:33AM  
02:31AM  
Apr-29-21 08:00PM  
08:00PM  
07:42PM  
07:05PM  
06:44PM  
04:47PM  
01:51PM  
12:36PM  
12:10PM  
08:41AM  
Apr-28-21 08:00PM  
08:00PM  
08:00PM  
04:02PM  
03:27PM  
01:32PM  
12:36PM  
12:28PM  
11:58AM  
10:03AM  
08:27AM  
08:12AM  
06:24AM  
04:23AM  
03:39AM  
03:09AM  
12:43AM  
Apr-27-21 08:00PM  
08:00PM  
08:00PM  
02:25PM  
02:19PM  
01:58PM  
12:23PM  
11:58AM  
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; and Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.